GlassScriptPhysician profile
Brooke Lw Nesmith
NPI 1295020667
$5,710.82
in general payments reported to CMS, 2019-2025
17 companies · $69.86 in 2025
The $69.86 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $192 · 2021: $2,418 · 2022: $2,455 · 2023: $80.69 · 2024: $95.41 · 2025: $69.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $245.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $4,573.83 | 2021-2022 | |
| Genentech USA, INC. | $265.08 | 2019-2023 | Vabysmo |
| Allergan, INC. | $262.90 | 2019-2020 | |
| Alimera Sciences, INC. | $87.70 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $75.92 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $72.89 | 2023-2024 | Eylea |
| Glaukos Corporation | $70.05 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $61.38 | 2019-2021 | |
| Amgen INC. | $52.48 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $35.80 | 2023 | Tepezza |
| Mallinckrodt Enterprises LLC | $31.20 | 2019 | |
| Ani Pharmaceuticals, INC. | $27.46 | 2025 | Yutiq |
| Astellas Pharma US INC | $26.75 | 2024 | Izervay |
| Abbvie INC. | $23.22 | 2022 | |
| Mallinckrodt Hospital Products INC. | $18.44 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $15.29 | 2022 | |
| Topcon Healthcare, INC. | $10.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$86,924.50 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Nesmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.